An AI Platform integrating imaging data and models, supporting precision care through prostate cancer’s continuum
Editorial by Prof Manolis Tsiknakis, Coordinator of ProCAncer-I project The ProCAncer-I project has completed the first year of its lifecycle at the end of October 2021. With this brief note key results and achievements of the first year are summarized in the sequel....
Within the ProCancer-I project, a total of nine clinical needs will be addressed utilizing artificial intelligence (AI) models trained on ProstateNET – a unified repository of 1.5 million images of prostate MRI acquired across the consortium. In the current landscape...
ProCAncer-I aspires to create the largest interoperable, high-quality multi-parametric Magnetic Resonance Imaging (mpMRI) dataset worldwide/globally comprising more than 11.000 retrospective and more than 6.000 prospective mpMRI examinations, including clinical data,...
Interview with prof. Daniele Regge (Clinical Coordinator of the ProCancer-I project) Q: In the case of prostate cancer there are several tests that can help clinicians in the decision process, for example, prediction algorithms based on PSA blood test and biopsy. Why...
A brief historical survey of European state-of-play, the open issues and the ProCAncer-I approach Over the last decade, Artificial Intelligence (AI) solutions to support the whole value-chain of medical imaging[1] has experienced a considerable acceleration. This...
By the Fundacao D. Anna Sommer Champalimaud e Dr. Carloss Montez Champalimaud (CF) Champalimaud Foundation (CF) is a private non-profit Portuguese institution, inaugurated in 2010 with the aim of advancing basic and translational world-leading research in...
By the FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (HULAFE) The FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (HULAFE) is a Spanish non-profit organization that carries out...
By the Massachusetts General Hospital (The General Hospital Corp) (QTIM) Our lab, the Quantitative Translational Imaging in Medicine (QTIM) lab, at the Athinoula A. Martinos Center for Biomedical Imaging of the Massachusetts General Hospital (MGH), focuses on...
Newsletter #2 Contents
The ProCAncer-I Consortium is organising a mini symposium under the scope Data Engineering in Cancer, chaired by prof. Dimitris Fotiadis and are inviting every interested stakeholder to participate. The mini symposium will take place during the IEEE EMBS International Conference on Data Science and Engineering in Healthcare, Medicine & Biology, in Malta (Hilton Malta Hotel) on December 7, 2023 – December 9, 2023, on the second day.
240 professionals from more than 20 countries registered for the workshop event ’Al and Cancer: Unleashing Opportunities, Overcoming Challenges’, coorganized by INCISIVE, EUCAIM, and the AI4HI cluster, with the local support of Medtronic and TIC Salut Social Foundation, the 7th of November in Madrid, Spain.
The EUCAIM (European Federation for Cancer Images) project is the cornerstone of the European Cancer Imaging Initiative, launched by the European Commission, within the framework of the European Beating Cancer Plan, emphasized Prof. Manolis Tsiknakis, as Coordinator of the ProCAncer-I project and Affiliated Professor at the Computational Biomedicine Laboratory (CBML), speaking at the Health IT conference.
EUCAIM unveils first release of groundbreaking platform to fuel collaborative innovation and data sharing across Europe